• AstraZeneca, Tempus Collaborate on AI Project for Cost Effective Industry R&D

    Bio-IT World | With the rising costs of pharmaceutical industry R&D, achieving breakthroughs in some of the hardest-to-treat diseases, such as cancer, is becoming increasingly expensive. This presents a major challenge to developers in bringing efficient, affordable treatments to patients. AstraZeneca and Tempus teamed up to create a framework that can gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community.

    Jul 17, 2024

  • At Harvard, Scientists Partner with AI Using the Language of Proteins

    Bio-IT World | Artificial intelligence (AI) is the new frontier in biomedical research, with large language models changing the way science is done from writing code and brainstorming research ideas to helping do research and conducting literature reviews. In some of its latest applications, generative AI has been used in designing molecules with insights produced at a scale and speed not possible with traditional deep learning methods alone.

    Jul 16, 2024

  • How Large Language Model-Based AI Will Transform Drug Safety & Regulatory Processes

    Bio-IT World | Training and validating intelligent automation systems for life sciences R&D purposes can undermine the business case. But the large language models (LLMs) used to power Generative AI (GenAI) is changing that and bolstering compliance, enabling on-the-fly data discovery, “in context” learning, and narrative extrapolation.

    Jul 12, 2024

  • New Biomarker Offers Hope of Detecting Alzheimer's in Asymptomatic Stages

    Bio-IT World | Until recently, all the available therapeutic options for treating Alzheimer’s disease were designed to reduce symptoms rather than address causes of the disease. But with two beta-amyloid antibodies now approved by the U.S. Food and Drug Administration, and tau-targeting agents in clinical trials, hopes are rising that Alzheimer’s progression can be delayed if not stopped.

    Jul 10, 2024

  • Illumina Acquires Fluent BioSciences Single-Cell Technology

    Bio-IT World | Illumina has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. Fluent Biosciences is now a wholly owned subsidiary of Illumina and was acquired with cash on hand.

    Jul 9, 2024

  • Regeneron Uses Voice-to-Text for Science-First Data Digitization Efforts for Animal Research

    Bio-IT World | When Regeneron began exploring how to digitize scientific information in lab environments, IT engineers didn’t begin by brainstorming their own ideas. They began by shadowing scientists.

    Jul 9, 2024